Literature DB >> 29491129

Comment on "MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma".

Sophie Voruz1, Filipe Martins2, Anne Cairoli2, Olaia Naveiras2, Krisztian Homicsko3, Edoardo Missiaglia4, Laurence de Leval4, Bettina Bisig4, Olivier Michielin3, Sabine Blum2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29491129      PMCID： PMC5830398          DOI： 10.3324/haematol.2017.186932

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  5 in total

1.  Histiocytic sarcoma: a population-based analysis of incidence, demographic disparities, and long-term outcomes.

Authors:  Anuhya Kommalapati; Sri Harsha Tella; Martin Durkin; Ronald S Go; Gaurav Goyal
Journal:  Blood       Date:  2017-11-28       Impact factor: 22.113

2.  Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma.

Authors:  Sophie Voruz; Anne Cairoli; Olaia Naveiras; Laurence de Leval; Edoardo Missiaglia; Krisztian Homicsko; Olivier Michielin; Sabine Blum
Journal:  Haematologica       Date:  2017-11-02       Impact factor: 9.941

3.  Haploinsufficiency for BRCA1 leads to cell-type-specific genomic instability and premature senescence.

Authors:  Maja Sedic; Adam Skibinski; Nelson Brown; Mercedes Gallardo; Peter Mulligan; Paula Martinez; Patricia J Keller; Eugene Glover; Andrea L Richardson; Janet Cowan; Amanda E Toland; Krithika Ravichandran; Harold Riethman; Stephen P Naber; Anders M Näär; Maria A Blasco; Philip W Hinds; Charlotte Kuperwasser
Journal:  Nat Commun       Date:  2015-06-24       Impact factor: 14.919

4.  Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1.

Authors:  Zoran Gatalica; Nurija Bilalovic; Juan P Palazzo; Ryan P Bender; Jeffrey Swensen; Sherri Z Millis; Semir Vranic; Daniel Von Hoff; Robert J Arceci
Journal:  Oncotarget       Date:  2015-08-14

5.  Response to anti-PD1 therapy with nivolumab in metastatic sarcomas.

Authors:  L Paoluzzi; A Cacavio; M Ghesani; A Karambelkar; A Rapkiewicz; J Weber; G Rosen
Journal:  Clin Sarcoma Res       Date:  2016-12-30
  5 in total
  2 in total

1.  A case of recurrent refractory cervical primary histiocytic sarcoma treated with pembrolizumab.

Authors:  Yu Furui; Takashi Kurata; Kazutoshi Komori; Eriko Uchida; Yosuke Miyairi; Akihiro Chiba; Yoshifumi Ogiso; Kazuo Sakashita
Journal:  Int Cancer Conf J       Date:  2022-06-30

2.  Favorable response to nivolumab in a young adult patient with metastatic histiocytic sarcoma.

Authors:  Shree Bose; Joanna Robles; Chad M McCall; Anand S Lagoo; Daniel S Wechsler; Gary R Schooler; David Van Mater
Journal:  Pediatr Blood Cancer       Date:  2018-09-30       Impact factor: 3.167
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.